AI can cut the need for standard testing techniques in colorectal cancer by 40%

Microsatellite Instability (MSI) is a genomic biomarker which represents ~15% of overall colorectal cancer (CRC) population - it plays an important role in determining treatment. For example, MSI patients show better prognoses and don’t benefit from chemotherapy in stage II. Furthermore, MSI status is reported to be predictive of response to immunotherapy across all solid tumors.

As demand for MSI screening for CRC patients (and beyond) increases, so too does the testing burden for pathologists and labs—creating bottlenecks and resource pressures. Current MSI screening techniques are MMR-IHC staining, MSI-PCR test, or Next-Generation Sequencing (NGS).

Owkin’s MSIntuit CRC® is a CE-marked AI diagnostic that provides a prescreen approach for MSI with digital pathology. With a sensitivity of ~95%, MSIntuit CRC® can help rule out 40% of CRC patients from reflex screening with standard MMR/MSI testing techniques.